FDA aducanumab coverage for business development, investment, and market access teams
Earlier
High impact NewsApr 9, 2026
FDA Approves Aduhelm: Key Details on Biogen's Alzheimer's Drug
FDA · Alzheimer's disease · 4 min
Dr. Sarah MitchellHigh impact AnalysisApr 1, 2026
FDA Breakthrough Therapy Designations: Advancing Alzheimer's Drug Development
FDA · Alzheimer's disease · 9 min
Dr. Sarah MitchellPopular topics
- Drug Approvals 1,128 articles
- Clinical Trials 634 articles
- Regulatory Updates 687 articles
- FDA News 502 articles
- Press Releases 443 articles
- Oncology 443 articles
- Rare Diseases 141 articles
Explore intelligence
- Global markets Cross-region command center
- Company directory Sponsor & marketer profiles
- Drug profiles INN & regulatory status
- Clinical trials hub Stage & therapy filters
- Pipeline programs R&D intelligence
- Patent landscape US & EP IP moats
- Event calendar Congress catalysts
- Regulatory reference Submission types & pathways